The Zhitong Finance App learned that on Monday, Kymera Therapeutics (KYMR.US) opened with a sharp rise of more than 40%, a record high, and is now reported at $95.66. According to the news, the expanded phase 1b atopic dermatitis test results of KyMR's drug KT-621 showed that deep STAT6 degradation was achieved in both the 100 mg and 200 mg dose groups, and the median degradation rate in skin and blood reached 94% and 98%, respectively, showing strong transformation ability from healthy volunteers to atopic dermatitis (AD) patients. KT-621 showed significant reductions in disease-related type 2 biomarkers in blood, including thymic activation-regulating chemokine (TARC) (74% decrease in baseline levels in patients with dupilumab AD studies), Eotaxin-3, IL-31, IgE, and core type 2 inflammation and related gene sets in skin lesions.

The Zhitong Finance App learned that on Monday, Kymera Therapeutics (KYMR.US) opened with a sharp rise of more than 40%, a record high, and is now reported at $95.66. According to the news, the expanded phase 1b atopic dermatitis test results of KyMR's drug KT-621 showed that deep STAT6 degradation was achieved in both the 100 mg and 200 mg dose groups, and the median degradation rate in skin and blood reached 94% and 98%, respectively, showing strong transformation ability from healthy volunteers to atopic dermatitis (AD) patients. KT-621 showed significant reductions in disease-related type 2 biomarkers in blood, including thymic activation-regulating chemokine (TARC) (74% decrease in baseline levels in patients with dupilumab AD studies), Eotaxin-3, IL-31, IgE, and core type 2 inflammation and related gene sets in skin lesions.